

SEQUENT SCIENTIFIC LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2013

(₹ in Lakhs)

S.No.	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		30-Jun-13 UNAUDITED	31-Mar-13 UNAUDITED	30-Jun-12 UNAUDITED	31-Mar-13 AUDITED
Part-I					
1	Income from operations				
a	Net Sales / Income from Operations (net of excise duty)	11,323.60	9,596.70	7,166.20	31,327.90
b	Other Operating Income	37.60	55.10	14.90	77.60
	Total income from operations (net)	11,361.20	9,651.80	7,181.10	31,405.50
2	Expenses				
a	Cost of materials consumed	5,332.00	5,950.30	3,289.10	17,905.90
b	Purchase of stock-in-trade	249.40	259.50	157.90	994.20
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	890.60	(133.90)	441.80	(1,291.40)
d	Employee benefits expenses	1,077.40	1,424.70	607.80	3,548.50
e	Depreciation and amortisation expenses	594.20	762.10	561.60	2,674.30
f	Other expenses	3,346.80	3,238.70	3,096.90	10,899.10
	Total expenses	11,490.40	11,501.40	8,155.10	34,730.60
3	Profit(Loss) from operations before other income, finance costs and exceptional items (1-2)	(129.20)	(1,849.60)	(974.00)	(3,325.10)
4	Other Income	76.70	25.60	86.40	249.00
5	Profit(Loss) from ordinary activities before finance cost and exceptional Items (3±4)	(52.50)	(1,824.00)	(887.60)	(3,076.10)
6	Finance cost	877.40	994.00	736.30	3,204.50
7	Profit(Loss) from ordinary activities after finance cost but before exceptional Items (5±6)	(929.90)	(2,818.00)	(1,623.90)	(6,280.60)
8	Exceptional items	-	-	-	-
9	Profit(Loss) from ordinary activities before tax (7±8)	(929.90)	(2,818.00)	(1,623.90)	(6,280.60)
10	Tax Expense	-	(432.30)	(105.90)	(831.00)
11	Net Profit/(Loss) from Ordinary activities after tax (9±10)	(929.90)	(2,385.70)	(1,518.00)	(5,449.60)
12	Extraordinary items	-	-	-	-
13	Net Profit/(Loss) for the period(11±12)	(929.90)	(2,385.70)	(1,518.00)	(5,449.60)
14	Paid-up equity share capital (Face Value per share Rs.10 each)	2,419.52	2,403.50	2,193.50	2,403.50
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	7,413.00
16.i	Earnings Per Share before Extraordinary Items for the period (Non-Annualised)				
	Basic (Rs.)	(3.86)	(10.05)	(6.92)	(24.01)
	Diluted (Rs.)	(3.86)	(10.05)	(6.92)	(24.01)
16.ii	Earnings Per Share after Extraordinary Items for the period (Non-Annualised)				
	Basic (Rs.)	(3.86)	(10.05)	(6.92)	(24.01)
	Diluted (Rs.)	(3.86)	(10.05)	(6.92)	(24.01)
Part-II					
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	No. of Shares	9,500,680	9,500,680	9,692,781	9,500,680
	% of Share Holding	39.27%	39.53%	44.19%	39.53%
2	Promoters and Promoter Group Shareholding				
a)	Pledged / Encumbered				
	1. No of shares	1,000,000	1,000,000	1,000,000	1,000,000
	2. Percentage of shares (as a % of the total shareholding of promoter & promoter group)	6.81%	6.88%	8.17%	6.88%
	3. Percentage of shares (as a % of the total share capital of the company)	4.13%	4.16%	4.56%	4.16%
b)	Non-encumbered				
	1. No of shares	13,694,511	13,534,511	11,242,410	13,534,511
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	93.19%	93.12%	91.83%	93.12%
	3. Percentage of shares (as a % of the total share capital of the company)	56.60%	56.31%	51.25%	56.31%
B	INVESTOR COMPLAINTS			Quarter ended 30 June 2013	
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			NIL	
	Disposed of during the quarter			NIL	
	Remaining unresolved at the end of the quarter			NIL	

Notes:

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on August 14, 2013.
- The Statutory Auditors have performed a limited review of the standalone financial results for the quarter ended as on June 30, 2013 of the Company as required by Clause 41 of the Listing Agreement.
- Segment Results

The Company has identified Pharmaceuticals and Specialty Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks and returns, the organisational structure and the internal reporting system.

Sl. No	Particulars	Quarter Ended			Year Ended
		30-Jun-13 UNAUDITED	31-Mar-13 UNAUDITED	30-Jun-12 UNAUDITED	31-Mar-13 AUDITED
1	Segment Revenue				
	a) Pharmaceuticals	9,569.24	8,207.92	6,247.83	26,242.69
	b) Specialty Chemicals	1,791.96	1,443.88	933.27	5,162.81
	Net Sales /Income from Operations	11,361.20	9,651.80	7,181.10	31,405.50
2	Segment Results				
	Profit or Loss before Tax and Interest from Each Segment				
	a) Pharmaceuticals	29.86	(1,377.21)	(684.49)	(2,698.85)
	b) Specialty Chemicals	287.13	303.13	(108.44)	785.27
	Total	316.99	(1,074.08)	(792.93)	(1,913.58)
	Less (i) Finance Cost	877.40	994.00	736.30	3,204.50
(ii) other unallocable expenditure net off unallocable income	369.49	749.92	94.67	1,162.52	
	Total Profit / (Loss) Before Tax	(929.90)	(2,818.00)	(1,623.90)	(6,280.60)
3	Capital Employed				
	a) Pharmaceuticals	24,953.32	22,817.11	24,579.05	22,817.11
	b) Specialty Chemicals	1,461.00	1,576.80	1,107.35	1,576.80
	c) Unallocated	(16,178.92)	(13,449.01)	(14,533.10)	(13,449.01)
	Total	10,235.40	10,944.90	11,153.30	10,944.90

- During the quarter the Company has issued 1.6 lakhs shares on conversion of warrants to its promoter group.
- On July 13, 2013, the Company signed a Letter of Intent with Shasun Pharmaceuticals Limited to form a Joint Venture Company to develop, manufacture and sell veterinary products inclusive of both Active Pharmaceutical Ingredients and formulations in the global market.
- Figures for the quarter ended 31 March 2013 are the balancing figures between audited figures and the published year-to-date figures up to the third quarter of the previous financial year.
- Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

For Sequent Scientific Limited

Place : Bangalore
Date : August 14, 2013

Dr. Gautam Kumar Das
Joint Managing Director